<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745378</url>
  </required_header>
  <id_info>
    <org_study_id>MPN-K - FROM/O2- 2017</org_study_id>
    <nct_id>NCT03745378</nct_id>
  </id_info>
  <brief_title>Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)</brief_title>
  <acronym>MPN-K</acronym>
  <official_title>Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is
      high and comparable to that of thrombosis. However, the identification of patient subgroups
      that might be at increased susceptibility of developing SC has not been systematically
      addressed. This international case-control study (MPN-K) is aimed to elucidate the prognostic
      role of JAK2V617F mutation in predicting the occurrence of SC in patients with classical MPN,
      polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For each recruited case with concomitant diagnosis of myeloproliferative neoplasms (MPN) and
      secondary cancer each participating center will provide up 3 control patients (1 control for
      each case could be accepted but the optimal number is 3). Controls are patients with
      myeloproliferative neoplasms and no history of cancer. Each control will be matched to the
      paired case for sex, age (+/- 3 years), date of MPN diagnosis (+/- 5 years), and MPN disease
      duration (+/- 3 years).

      Each control is censored at the date of the secondary cancer occurrence in his matched case
      (index date).

      Data will be collected retrospectively from pre-existing medical records and reported by each
      center on a web-based and validated eCRF developed to record y all study data. In order to
      maintain patient privacy, all data records will be treated anonymously and no personal data
      to identify patient will be recorded: patients will be identified in the study by an
      alphanumeric code.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with secondary cancers after diagnosis of Polycythemia Vera (PV), Essential Trombocythemia (ET) and Myelofibrosis (MF)</measure>
    <time_frame>10 year from diagnosis of PV, ET or MF</time_frame>
    <description>The ratio of number of patients showing JAK2V617F mutation on the number of patients not exposed to this mutation will be calculated in the group of subjects experiencing second cancer after diagnosis of PV, ET and MF (defined as 'cases') and related (odds ratio) with the ratio of patients exposed on those not exposed to JAK2V617F mutation in the group of subjects with no experience of secondary cancers after diagnosis of PV, ET and MF (this group is defined as 'Control' group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with secondary cancers after diagnosis of Polycythemia Vera (PV), Essential Trombocythemia (ET) and Myelofibrosis (MF) in subgroups of subjects exposed to potential risk factors at diagnosis</measure>
    <time_frame>10 year from diagnosis of PV, ET or MF</time_frame>
    <description>Characteristics at diagnosis of patients with PV, ET and MF (including other mutations) with occurrence of second cancers (SC) are decribed and compared with those not experiencing SC after diagnosis of myloproliferative neoplasm; the ratio of number of patients exposed to potential risk factors on the number of subjects not exposed will be calculated in the group cases (as defined for primary outcome measure) and related (odds ratio) with the ratio of patient exposed versus not exposed calculated in the subgroup of control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with secondary cancers after diagnosis of Polycythemia Vera (PV), Essential Trombocythemia (ET) and Myelofibrosis (MF) in the subgroups exposed to treatment</measure>
    <time_frame>10 year from diagnosis of PV, ET or MF</time_frame>
    <description>Group of patients exposed and not exposed to different class of treatments for PV, ET and MF are compared and related in the group of cases and control</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1881</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JAK2V617F mutation</intervention_name>
    <description>JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Matching characteristics for inclusion: sex, age at diagnosis of MPN (+/-3 years), date of
        MPN diagnosis (+/- 5 years), and MPN disease duration (+/- 3 years).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Philadelphia-negative Myeloproliferative Neoplasms (MPN) according to
             PVSG, 2008 and 2016 WHO criteria, including:

          -  Polycythemia Vera (PV)

          -  Essential Thrombocythemia (ET)

          -  Myelofibrosis (MF), including both primary and secondary MF

          -  Diagnosis performed between 1st January 2000 to 31 December 2016

          -  Diagnosis of secondary cancer(s) performed concurrently or subsequently the diagnosis
             of MPN

        Exclusion Criteria:

        - Diagnosis of cancer occurred before the diagnosis of MPN (PV, ET, MF)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziano Barbui, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione per la Ricerca Ospedale Maggiore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Finazzi, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST-Papa Giovanni XXIII</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palacky University and University Hospital Olomouc, Faculty of Medecine</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital RWTH - Department Oncology, Hematology, Hemostaeseology and stem cell transplantation</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Academic Medical Center</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Asti - A.S.L. AT Ospedale Cardinal Massaia - S.C. Oncologia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST- Papa Giovanni XXIII - UOC Ematologia</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Orsola - Malpighi - UO Ematologia</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Emostasi &quot;G. Rodolico&quot; Dipartimento di Scienze Mediche, Chirurgiche e Tecnologiche Avanzate &quot;G.F. Ingrassia&quot; Università degli Studi di Catania</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle di Cuneo- Divisione di Ematologia,</name>
      <address>
        <city>Cuneo</city>
        <zip>2100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi di Firenze CRIMM- Center of Research and Innovation of Myeloproliferative Neoplasms - Department of Experimental and Clinical Medicine, University of Florence</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico - UOC Ematologia</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele Unità Operativa di Ematologia e Trapianto Midollo Osseo</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST MONZA Ospedale San Gerardo Clinica Ematologica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo S.C Ematologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL IRCCS di Reggio Emilia Presidio Osp. Arcispedale Santa Maria Nuova - Unità Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS UCSC Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette - S.C. Ematologia U</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Roma - Unità di Ematologia</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza - U.O.C di Ematologia</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, Hematology Department</name>
      <address>
        <city>Barcellona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar - Haematologia Clinica</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d' Hebron - Unit Hematology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Santiago De Campostela - Service of Hematology</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita Clinico Universitario - Hematology Department</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miguel Servet University Hospital</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust - Unit Haematology</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative neoplasms</keyword>
  <keyword>Secondary cancer</keyword>
  <keyword>JAK2V617F mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

